CN119497589A - 用于设计和产生增进人际亲密感心智状态的治疗组合、组合物和方法 - Google Patents

用于设计和产生增进人际亲密感心智状态的治疗组合、组合物和方法 Download PDF

Info

Publication number
CN119497589A
CN119497589A CN202380038385.8A CN202380038385A CN119497589A CN 119497589 A CN119497589 A CN 119497589A CN 202380038385 A CN202380038385 A CN 202380038385A CN 119497589 A CN119497589 A CN 119497589A
Authority
CN
China
Prior art keywords
agent
receptor
therapeutic combination
agonist
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038385.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·瑞雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mood Design Laboratory Co ltd
Original Assignee
Mood Design Laboratory Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mood Design Laboratory Co ltd filed Critical Mood Design Laboratory Co ltd
Publication of CN119497589A publication Critical patent/CN119497589A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380038385.8A 2022-03-09 2023-03-09 用于设计和产生增进人际亲密感心智状态的治疗组合、组合物和方法 Pending CN119497589A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318369P 2022-03-09 2022-03-09
US63/318,369 2022-03-09
PCT/US2023/014926 WO2023172701A2 (en) 2022-03-09 2023-03-09 Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates

Publications (1)

Publication Number Publication Date
CN119497589A true CN119497589A (zh) 2025-02-21

Family

ID=87935763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038385.8A Pending CN119497589A (zh) 2022-03-09 2023-03-09 用于设计和产生增进人际亲密感心智状态的治疗组合、组合物和方法

Country Status (11)

Country Link
US (1) US20250177354A1 (https=)
EP (1) EP4489649A2 (https=)
JP (1) JP2025509432A (https=)
KR (1) KR20250011101A (https=)
CN (1) CN119497589A (https=)
AU (1) AU2023232712A1 (https=)
CA (1) CA3245622A1 (https=)
CR (1) CR20240417A (https=)
IL (1) IL315512A (https=)
MX (1) MX2024011043A (https=)
WO (1) WO2023172701A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns

Also Published As

Publication number Publication date
CR20240417A (es) 2025-03-04
JP2025509432A (ja) 2025-04-11
CA3245622A1 (en) 2023-09-14
US20250177354A1 (en) 2025-06-05
KR20250011101A (ko) 2025-01-21
EP4489649A2 (en) 2025-01-15
IL315512A (en) 2024-11-01
MX2024011043A (es) 2024-12-06
AU2023232712A1 (en) 2024-10-17
WO2023172701A2 (en) 2023-09-14
WO2023172701A3 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
WO2022150525A1 (en) Mdma in the treatment of alcohol use disorder
AU2022413759A1 (en) Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US20240024340A1 (en) Compositions and Methods For Treating Migraine
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CN118267382A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
CN113908156A (zh) 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
EP3941469A1 (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
WO2022238507A1 (en) Therapeutic aminoindane compounds and compositions
CN119497589A (zh) 用于设计和产生增进人际亲密感心智状态的治疗组合、组合物和方法
TW201242600A (en) Treatment of cognitive dysfunction in schizophrenia
US20240122895A1 (en) Entactogen-assisted therapy for alcohol use disorder and addiction-related conditions and comorbidities
KR20250153795A (ko) 실로시빈 유사체로 장애를 치료하는 방법
CA3054679A1 (en) Method for preventing or treating autism spectrum disorders by benzoic acid salt
US20260041667A1 (en) Prescription digital therapeutics
Li Treatment of depression from both biological and psychological aspects
WO2026068950A1 (en) Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
US20070225334A1 (en) Methods for treating cognitive and other disorders
KR20260003282A (ko) 주사식 약학적 제형
Maged Stimulants, Ecstasy, and Other’Party Drugs'
Zeise Clinical Neuropharmacology
WO2023219548A1 (en) Selective dopamine increase
Kossowsky et al. Systematic Reviews of Pharmacological and Non-Pharmacological Psychiatric Interventions
KR20240167886A (ko) 산후 우울증의 치료를 위한 5-메톡시-n,n-다이메틸트립타민
Greene Miscellaneous compounds
Talavera et al. Rapid Fire Pharmacy Review

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination